Basal vs. luminal a breast cancer subtypes: A matched case-control study using estrogen receptor, progesterone receptor, and HER-2 as surrogate markers

Medical Oncology

Volumn 26, Issue 3, 2009, Pages 372-378

  Ibrahim, Ezzeldin ^a   Al Gahmi, Aboelkhair M ^a   Zeenelin, Ahmed A ^a   Zekri, Jamal M ^a   Elkhodary, Tawfik R ^a   Gaballa, Hussein E ^a   Fawzy, Ehab E ^a   El Sayed, Mohamed E ^a   Alzahrani, Mohamed S ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Basal; Breast cancer; Luminal A; Triple negative

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BASAL BREAST CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER INVASION; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SIZE; CARCINOMA IN SITU; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE MARKER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUMINAL BREAST CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MIDDLE AGED; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 77954088072     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-008-9131-6     Document Type: Article

References (26)

1. CM Perou T Sorlie MB Eisen, et al. 2000 Molecular portraits of human breast tumours Nature 406 747 52 10.1038/35021093 10963602 10.1038/35021093 1:CAS:528:DC%2BD3cXmt1CnsLw%3D
2. T Sorlie R Tibshirani J Parker, et al. 2003 Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci USA 100 8418 23 10.1073/pnas.0932692100 12829800 10.1073/pnas.0932692100 1:CAS:528:DC%2BD3sXlsFGntLk%3D (Pubitemid 36842560)
3. T Sorlie CM Perou R Tibshirani, et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 10869 74 10.1073/pnas.191367098 11553815 10.1073/pnas.191367098 1:CAS:528:DC%2BD3MXntVGmsbo%3D (Pubitemid 32878711)
4. JD Brenton LA Carey AA Ahmed C Caldas 2005 Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 23 7350 60 10.1200/JCO.2005.03.3845 16145060 10.1200/JCO.2005.03.3845 1:CAS:528:DC%2BD2MXhtF2nsLrJ (Pubitemid 46202348)
5. LG Fulford JS Reis-Filho K Ryder, et al. 2007 Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival Breast Cancer Res 9 R4 10.1186/bcr1636 17217540 10.1186/bcr1636 (Pubitemid 350215157)
6. R Rouzier CM Perou WF Symmans, et al. 2005 Breast cancer molecular subtypes respond differently to preoperative chemotherapy Clin Cancer Res 11 5678 85 10.1158/1078-0432.CCR-04-2421 16115903 10.1158/1078-0432.CCR-04-2421 1:CAS:528:DC%2BD2MXos1Cjs7k%3D (Pubitemid 41170290)
7. LA Carey EC Dees L Sawyer, et al. 2007 The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 2329 34 10.1158/1078-0432.CCR-06-1109 17438091 10.1158/1078-0432.CCR-06-1109 1:CAS:528:DC%2BD2sXkt1enur0%3D (Pubitemid 46698581)
8. R Dent M Trudeau KI Pritchard, et al. 2007 Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res 13 4429 34 10.1158/1078-0432.CCR-06-3045 17671126 10.1158/1078-0432.CCR-06-3045 (Pubitemid 47219710)
9. KR Bauer M Brown RD Cress CA Parise V Caggiano 2007 Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry Cancer 109 1721 8 10.1002/cncr.22618 17387718 10.1002/cncr.22618 (Pubitemid 46668532)
10. H Bartelink MJ van de Vijver 2007 Gene expression profiling and histopathological characterization of triple negative/basal like breast carcinomas Breast Cancer Res 9 R65 10.1186/bcr1771 17910759 10.1186/bcr1771 (Pubitemid 350187481)
11. CA Livasy G Karaca R Nanda, et al. 2006 Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma Mod Pathol 19 264 71 10.1038/modpathol.3800528 16341146 10.1038/modpathol.3800528 1:CAS:528:DC%2BD28Xlt1eqtw%3D%3D (Pubitemid 43117611)
12. CU Ihemelandu LD Leffall Jr RL Dewitty TJ Naab HM Mezghebe KH Makambi, et al. 2007 Molecular breast cancer subtypes in premenopausal and postmenopausal J Surg Res 143 109 18 17950079 10.1016/j.jss.2007.03.085 1:CAS:528: DC%2BD2sXhtF2htrbN (Pubitemid 47562451)
13. PL Nguyen AG Taghian MS Katz A Niemierko RF Abi Raad WL Boon JR Bellon JS Wong BL Smith JR Harris 2008 Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy J Clin Oncol 26 14 2373 8 18413639 10.1200/JCO.2007.14.4287
14. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 205 16 10.1093/jnci/92.3.205 10655437 10.1093/jnci/92.3.205 1:STN:280: DC%2BD3c7it1Gitg%3D%3D
15. EL Kaplan P Meier 1958 Nonparametric estimation from incomplete observations J Am Stat Assoc 53 457 80 10.2307/2281868 10.2307/2281868
16. N Mantel W Haenszel 1959 Statistical aspects of the analysis of data from retrospective studies of disease J Natl Cancer Inst 22 719 48 13655060 1:STN:280:DyaG1M%2FosVOhtQ%3D%3D
17. DR Cox 1972 Regression models and life-tables (with discussion) J Roy Stat Soc (B) 34 187 220
18. JS Reis-Filho AN Tutt 2008 Triple negative tumours: a critical review Histopathology 52 1 108 18 18171422 1:STN:280:DC%2BD1c%2FgsF2mtg%3D%3D Jan
19. LG Fulford DF Easton JS Reis-Filho, et al. 2006 Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast Histopathology 49 22 34 10.1111/j.1365-2559.2006.02453.x 16842243 10.1111/j.1365-2559.2006.02453.x 1:STN:280:DC%2BD28vitFOitQ%3D%3D (Pubitemid 43972917)
20. H Tsuda T Takarabe F Hasegawa T Fukutomi S Hirohashi 2000 Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases Am J Surg Pathol 24 197 202 10.1097/00000478-200002000-00005 10680887 10.1097/00000478-200002000-00005 1:STN:280:DC%2BD3c7ktlWhsA%3D%3D (Pubitemid 30078708)
21. EA Rakha ME El-Sayed AR Green AHS Lee JF Robertson IO Ellis 2007 Prognostic markers in triple-negative breast cancer Cancer 109 1 25 32 17146782 10.1002/cncr.22381 1:CAS:528:DC%2BD2sXhtVKrtLY%3D (Pubitemid 46120191)
22. BG Haffty Q Yang M Reiss T Kearney SA Higgins J Weidhaas L Harris W Hait D Toppmeyer 2006 Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer J Clin Oncol 24 36 5652 7 10.1200/JCO.2006.06.5664 17116942 10.1200/JCO.2006.06.5664 Dec 20 (Pubitemid 46631305)
23. TO Nielsen FD Hsu K Jensen, et al. 2004 Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 5367 74 10.1158/1078-0432.CCR-04-0220 15328174 10.1158/1078-0432.CCR-04-0220 1:CAS:528:DC%2BD2cXmvFSlt7k%3D (Pubitemid 39100473)
24. B Kreike M van Kouwenhove H Horlings B Weigelt H Peterse H Bartelink MJ van de Vijver 2007 Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas Breast Cancer Res 9 5 R65 10.1186/bcr1771 17910759 10.1186/bcr1771 (Pubitemid 350187481)
25. S Rodenhuis M Bontenbal QGCM van Hoesel, et al. 2006 Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer Ann Oncol 17 588 96 10.1093/annonc/mdl001 16446318 10.1093/annonc/mdl001 1:STN:280:DC%2BD287mslSksA%3D%3D
26. UA Nitz O Gluz A Herr, et al. 2006 Retrospective analysis of WSG AM01 tandem high dose chemotherapy trial in high risk primary breast cancer: a hypothesis generating study Proc Am Soc Clin Oncol 24 665 (Abstr)